Introduction
The field of T regulatory (Treg) or T suppressor cells was reborn by the observations of Sakaguchi et al. (1995) that depletion of the minor population of CD4 + T cells that coexpress CD25 from a population of normal adult CD4 + T cells generated a population of cells that induced a spectrum of autoimmune diseases when transferred to an immunocompromised recipient. Cotransfer of the CD25 + cells prevented the development of autoimmunity.
The critical question that needs to be addressed is the mechanism of action of these Treg cells in vivo. It was thought that the development of an in vitro model system (Thornton and Shevach, 1998; Takahashi et al., 1998) for the analysis of Treg cell function would offer major insights into the mechanism of action of Treg cells in vivo. However, the in vitro model systems have identified a long list of molecules and processes that contribute to Treg cellsuppressive activities and it remains unclear whether any of the conclusions drawn from these studies shed light on how Treg cells function in vivo. A detailed analysis of Treg cell function is further confounded by the large number of different cell types that are purported to be directly targeted by Foxp3 + Treg cell (Box 1). Although multiple T cell subsets (e.g., Tr1 cells, Th3 cells, Th1 and Th2 cells, etc.) can certainly exert negative immunoregulatory effects by producing immunomodulatory cytokines (IL-10, TGF-b), I will confine this discussion to CD4 + Foxp3 + Treg cells that develop in both the thymus and periphery and represent the major Treg cell populations that are critical for immune homeostasis.
Lessons to Be Learned from In Vitro Suppression Assays: Responder T Cells as Targets Box 2 summarizes some of the major conclusions drawn from the in vitro suppression assays performed with both human and mouse Foxp3 + Treg cells that are agreed to by most workers in the field. Numerous controversial issues remain regarding the interpretation of these assays and I will discuss several of the ones that I regard as most critical. First, what is the cellular target for Treg cell-mediated suppression in vitro? Suppression assays are performed in two distinct ways. In some studies, a source of antigen-presenting cells (APCs, most often irradiated T-depleted spleen cells or unirradiated dendritic cells [DCs] ) is added and the stimulus for activation is soluble anti-CD3, whereas in other studies bead-coupled or plate-bound antibodies together with anti-CD28 are used in the complete absence of APCs. In the former case, the target of Treg cell suppression can be the APC, the responder cells, or both, whereas in the latter situation the responder T cells are the only targets. This section will focus on potential mechanisms of suppression that target responder T cells (Figure 1 ), whereas the next section will deal with mechanisms that potentially target APCs. As is apparent from the discussion to follow, this division is somewhat arbitrary and some mechanisms can target both cell types.
Murine Treg cells are potent suppressors of T cell proliferation in the presence of soluble anti-CD3 and APCs and are very inefficient suppressors (requiring a high ratio of suppressors to responders) when anti-CD3 is coupled to a solid phase in the presence or absence of anti-CD28. Furthermore, in the presence of anti-CD28 and soluble anti-CD3, suppression was frequently abrogated secondary to induction of high amounts of IL-2 production by the responder cells (Thornton and Shevach, 1998, 2000; Thornton et al., 2004b) . These results raised the possibility that the APC is the primary target of the Treg cells, but suppression of the response of transgenic CD8 + T cells to stimulation with MHC class I peptide tetramers by preactivated Treg cells was readily observed in the absence of a source of professional APC, suggesting that Treg cells could also efficiently target responder T cells (Piccirillo and Shevach, 2002) .
Many studies of human Treg cell function have used beadcoupled reagents as the stimulus in cocultures and again substantial suppression was observed only at high suppressor to responder ratios. It is unclear which assay system should be used, but it is obvious that the two assays may be measuring (Thornton and Shevach, 1998; Takahashi et al., 1998; Oberle et al., 2007) . Furthermore, the addition of exogenous IL-2 had no effect on the Treg cell-mediated suppression of IL-2 mRNA production (Thornton et al., 2004a; Oberle et al., 2007) . The role of IL-2 consumption in the suppressive mechanism of Treg cells is under dispute. Treg cells express all three components of the high-affinity IL-2R-CD25, CD122, and CD132-and IL-2 is essential not only for Treg cell homeostasis in vivo (Yu et al., 2009) , but also for their efficient suppressor function in vitro (Thornton et al., 2004a) . One study (Pandiyan et al., 2007) has raised the possibility that Treg cells may compete with Foxp3
À T cells for IL-2, consume it, and inhibit the proliferation of Foxp3 À T cells, resulting in a form of apoptosis dependent on the proapoptotic factor Bim. Curiously, this study is the only one to claim that Treg cells do not inhibit IL-2 production by responder T cells. Although it has been widely assumed that Foxp3 + Treg cells express high numbers of high-affinity IL-2 receptors that would render them efficient competitors, quantitation of the number of high-affinity IL-2 receptors on Foxp3 + T cells has never been determined and is dependent not on the expresssion of CD25, the low-affinity IL-2 receptor, but on the expressions of CD122 and CD132 that are required to form the high-affinity IL-2 receptor complex. In a hybrid system where human Treg cells were shown to be capable of efficiently suppressing the proliferation of mouse responder cells, the addition of antihuman CD25 that blocks IL-2 binding also had no effect on the function of the human Treg cells (Tran et al., 2009a) . Taken together, these studies argue against IL-2 consumption as a major pathway of Treg cell suppression in vitro, but IL-2 consumption may influence the results of suppression assays when activated conventional T cells contaminate Treg cells used in the assays.
Could a soluble suppressor cytokine mediate Treg cell suppressor function in vitro? It should be emphasized that the failure to observe suppression when Treg cells are separated from the responder cells by a membrane does not rule out the possibility that Treg cells secrete an as yet uncharacterized cytokine that functions in a gradient fashion and requires proximity between suppressor and responder. It is also possible that the production of a suppressor cytokine by either the Foxp3 + Treg cell or by the responder cell might require cell contact between the Treg and the responder T cell. Another secreted molecule that potentially may play a role in Treg cell-DC or Treg cell-T cell interactions is galectin-1, a member of a highly conserved family of b-galactoside binding proteins (Garin et al., 2007) . Galectin-1 is secreted as a homodimer, and binds to many glycoproteins including CD45, CD43, and CD7. The consequences of galectin binding correlate with those induced by Treg cells in responder cells including cell cycle arrest and apoptosis and inhibition of the production of proinflammatory cytokines. It is not clear whether galectin-1 acts as a soluble cytokine or mediates it effects via cell-cell contact. Galectin-1 is preferentially expressed in Treg cells and is upregulated upon T cell receptor (TCR) activation. Blocking of galectin-1 markedly reduced the inhibitory effects of human and mouse Treg cells and Treg cells from galectin-1-deficient mice had reduced Treg cell activity. Another member of the galectin family, Galectin-10, was identified by a proteomics approach as being selectively expressed by human Treg cells (Kubach et al., 2007) . Galectin-10 is exclusively expressed intracellularly and is probably not directly involved in the contact-dependent suppression mediated by Treg cells. However, galectin-10-specific siRNA treatment reversed the anergic state of human Treg cell in vitro resulting in increased proliferation upon activation and a partial abrogation of their suppressive activity. The intracellular ligands for galectin-10 have not been identified.
One other potential mechanism for Treg-mediated suppression of responder T cells would be cytolysis of target cells. (Misra et al., 2004; Serra et al., 2003) . It was also claimed that Treg cell-mediated suppression of proliferation could be reversed by anti-CTLA-4 or its Fab fragment in vitro, but the inhibitory effects of anti-CTLA-4 were not seen in all studies (Thornton et al., 2004b) . Very few studies have examined the effects of anti-CTLA-4 in vivo, but it has been shown that treatment of mice with anti-CTLA-4 abrogates suppression of IBD mediated by Treg cells (Read et al., 2006) .
The function of CTLA-4 on Treg cells has been somewhat clarified by the recent demonstration that animals with a selective deletion of expression of CTLA-4 develop systemic autoimmunity at 7 weeks of age (Wing et al., 2008) . Thus, CTLA-4 deficiency in Treg cells alone is sufficient to cause fatal disease, and maintenance of its expression in activated effector T cells is insufficient to prevent this outcome. Selective CTLA-4 deficiency does not alter the development or homeostasis of Treg cells or render them pathogenic. These cells remain anergic, but are less suppressive in vitro than are their wild-type counterparts when DCs were used as stimulator cells. CTLA-4-deficient Treg cells are less suppressive in vivo as indicated by the fact that immunodeficient mice reconstituted with total CD4 + T cells from these mice show enhanced immune responses to transplanted tumors. It has been proposed that the interaction of CTLA-4 on Treg cells with its ligands, CD80 and CD86, on DCs blocks the subsequent increase of CD80 and CD86 expression or even downregulates CD80 and CD86 expression induced by antigen-specific effector cells (Onishi et al., 2008) . Treg cells from mice lacking CTLA-4 are defective when compared to Treg cells from wild-type mice in preventing increased expression of CD80 and CD86 in DCs, and the addition of anti-CTLA-4 Fab fragments into cultures of wild-type Treg cells and DCs partially inhibited the suppression of CD80 and CD86 expression (Wing et al., 2008) . The conclusions drawn from these studies are that inhibition of CD80 and CD86 expression by Treg cells limits the capacity of the DCs to stimulate naive T cells through CD28 resulting in immune suppression. The biochemical nature of the extrinsic signal transduced to the DCs by the interaction of CTLA-4 with CD80 and CD86 remains to be characterized. One mechanism that may mediate the downregulation of CD80 and CD86 expression is trogocytosis, a process in which lymphocytes extract surface molecules through the immunological synapse from the antigen-presenting cells to which they are conjugated (Joly and Hudriser, 2003; Qureshi et al., 2008) . It is also possible that CTLA-4 on Treg cells may interact with CD80 and CD86 that are expressed on activated Foxp3 À T cells and in some manner downregulate effector T cell functions (Paust and Cantor, 2005) .
A number of other mechanisms have been proposed by which Treg cells either abrogate the antigen-presenting activity of DCs Removal of extracellular ATP by CD39 may allow the Treg cell to enter inflamed regions and permit the Treg cell to quench ATP-driven proinflammatory processes on multiple cell types, particularly DCs. CD39-deficient Treg cells are dysfunctional because they are not anergic and proliferate in response to anti-CD3 and anti-CD28 stimulation in the absence of exogenous IL-2. CD39-deficient cells are also about 50% less effective at suppressing stimulation of T cells from A2A-deficient mice when compared with the ability of WT T cells to suppress WT T cell proliferation. The immunomodulatory effects of removal of ATP by CD39 can be amplified by the generation of adenosine. Adenosine can be generated by CD39 in concert with the 5 0 -ecto-nucleoside CD73, which dephosphorylates the CD39 product, AMP (Deaglio et al., 2007 À T cells in vivo (Fahlen et al., 2005) . Importantly, the function of Tgfb1 À/À Treg cells is abrogated by anti-TGF-b, indicating that TGF-b is absolutely required for protection from IBD, but can be derived from a non-Treg cell source. In contrast, mice with a T cell-specific deletion of TGFb production (Li et al., 2007) or processing do develop an autoimmune syndrome including IBD. The differences between these studies are unclear, but may relate to the flora in different animal colonies. It is also possible that Two studies have used two-photon laser scanning microscopy to examine potential interactions between antigen-specific Treg cells and DCs in lymph nodes (Tang et al., 2006; Tadokoro et al., 2006) . In the absence of antigen-specific Treg cells, an arrest of antigen-specific effector T cells interacting with DCs was observed, whereas in the presence of Treg cells, the arrest of effector T cells was markedly diminished. Treg cells were also capable of suppressing the formation of stable clusters of diabetogenic TCR transgenic T cells in isolated pancreatic lymph nodes. In both of these studies, the conventional T cells showed diminished cytokine production in the lymph nodes. Importantly, stable Treg cell-T effector cell interactions or simultaneous interactions between Treg cell-T effector cell and the DCs were not seen. Although one might conclude from these studies that Treg cells exert their suppressive actions on DCs in secondary lymphoid organs by diminishing the activation of the DCs, by inhibiting the ability of DCs to physically interact with effectors cells, or by blocking the capacity of DCs to present antigen, no direct effects of the Treg cells on DC function were seen in these studies.
The majority of studies have shown that antigen-specific Treg cells are more potent at suppressing the induction of autoimmune disease than polyclonal populations. Klein et al. (2003) attempted to model the mechanisms by which antigen-specific Treg cells inhibit effector T cell activation by cotransferring antigen-specific Treg cells and naive T cells followed by priming with antigen in incomplete adjuvant. Treg cells were stimulated by antigen to proliferate almost as strongly as naive CD4 + T cells and a marked accumulation of Treg cells was observed in antigen-draining lymph nodes. Both Treg and non-Treg cells expanded in an antigen-dependent manner and produced typical patterns of cytokines, the Treg IL-10 and the naive T cells IL-2 and IFN-g. At later time points, effector cell expansion ceased, but when the few effector cells remaining were restimulated, they appeared to be fully competent producers of both IL-2 and IFN-g. It was concluded from these studies that, in contrast to the in vitro studies, no influence of Treg cells on the differentiation of naive T cells could be observed; the responder cells may have died or migrated from the draining nodes.
Very different conclusions were drawn from a study in which antigen-specific TGF-b-induced Treg cells were used to prevent gastritis (DiPaolo et al., 2007) . The induced Treg cells were long lived in vivo, maintained Foxp3 expression, and protected mice from disease. The major effect of the Treg cells was to inhibit the expansion of the cotransferred effector cells on day 5 after transfer. Most importantly, DCs that had been exposed to Treg cells in vivo had a reduced capacity to present the endogenous autoantigen compared to those from noninjected mice. It thus appears that one mechanism by which Treg cells exert their function in vivo is by reducing the ability of DCs to prime autoreactive T cells, hence stopping the autoimmune response before it even starts. This study supports the experiments that demonstrate that the presence of Treg cells results in fewer long-lasting interactions between effector T cells and DCs, but also demonstrates that the Treg cells exert their negative effects by decreasing the stimulatory capacity of DCs rather than by competing with the effectors for antigen or by acting directly on the effector cells to prevent their interaction with DCs.
In contrast to the effects of antigen-specific Treg cells on CD4 
Reversal of Suppression
Although the mechanism of Treg cell-mediated inhibition of T cell activation remains unknown, one approach to determining potential cell surface antigens involved in this process has been to reverse suppression with antibodies to candidate antigens. One member of the tumor necrosis receptor superfamily (TNFRSF), the GITR (TNFRSF18), has been claimed to play an important role in regulation of T cell suppressor activity. Both a polyclonal antiserum and a mAb to the GITR were initially reported to reverse suppression mediated by freshly isolated Treg cells (Shevach and Stephens, 2006 (Valzasina et al., 2005) . If Treg cells are preincubated with an agonist anti-OX40, they lose the ability to suppress effector T cells in an in vivo mouse model of graft versus host disease. Reversal of Treg cell suppression by anti-OX40 also resulted in complete rejection of already established tumors (Piconese et al., 2008) . However, it is difficult to rule out that persistence of the agonistic antibody also costimulated effector T cells that expressed OX40 after activation. It remains possible that engagement of OX40 in some manner abolishes Treg cell suppression, but the effects of anti-OX40 in vivo could also be secondary to partial depletion of Treg cells by the antibody. Curiously, a recent study has demonstrated that Treg cells can inhibit the release of allergic mediators from mast cells and that inhibition was mediated by OX40 expressed on the Treg cell interacting with OX40L expressed on the mast cells (Gri et al., 2008) . Thus, OX40 in some cases can function as a suppressor effector molecule.
Engagement of Toll-like receptor 2 (TLR2) on Treg cells has also been claimed to reverse the suppressive effects of mouse Treg cells in some studies (Liu et al., 2006; Sutmuller et al., 2006) . In contrast, the suppressive function of human Treg cells is enhanced by engagement of TLR5 by its ligand, flagellin (Crellin et al., 2005) . The major problem with the interpretation of these studies is that the TLR are also expressed at low amounts on Foxp3 À T cells and at much higher amounts on multiple cell types in the innate immune system. Contamination of the preparations of Treg cells used in these studies by non-Treg cells may have contributed to the discrepant results. The other major problem with the interpretation of studies on reversal of suppression is that we have very little understanding of the biochemical pathway used by the Treg cells and even less understanding of the signals induced by those agents that are claimed to reverse suppression. On the brighter side, it is clear that Treg cell-mediated suppression can be overcome by costimulation of effector cells (e.g., via the GITR or OX40). Reagents that stimulate these pathways may be valuable adjuncts to enhance responses both to tumor vaccines and responses to weak vaccines to infectious agents.
Concluding Comments
The in vitro models of Treg cell function certainly suggest that Treg cells may use multiple mechanisms to suppress immune responses. Yet, how many of the mechanisms are actually operative in vivo? Have we now exhausted the list of potential suppressor mechanisms or is a critical suppressor pathway yet to be discovered? One argument against the existence of an as yet to be discovered ''major player'' is that one would have expected that a mutation in such a pathway would have led to the development of a severe autoimmune syndrome similar to that seen with mutations of Foxp3. A more important question is whether our current understanding of Treg cell suppressor mechanisms offers any insight into how Treg cell function can be manipulated in vivo. For example, can we transiently and selectively downregulate Treg cell function prior to the administration of a tumor vaccine? Alternatively, how can we enhance Treg cell numbers or effectiveness without inducing systemic immunosuppression? Even if we can increase Treg cell numbers by using cellular biotherapy with expanded polyclonal or antigen-specific Treg cells to treat autoimmune disease, will the expanded Treg cells survive in vivo? How often would such therapy have to be administered? Will Treg cells induce longlasting antigen-specific tolerance via an infectious tolerance mechanism? Some of these questions are likely only to be answered by well-designed and well-controlled clinical trials.
